# Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

> **NCT07128381** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 66 (estimated)

## Conditions studied

- Myelofibrosis (MF)
- Chronic Myelomonocytic Leukemia (CMML)

## Interventions

- **DRUG:** Axatilimab (SNDX-6352)
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT07128381
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-02
- **Primary completion:** 2031-07-31
- **Final completion:** 2033-07-31
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07128381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07128381, "Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07128381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*